Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Coaching and question prompt list improve patient-oncologist communication

09 Feb 2017
Medical Enquiries from Friends and Family: Setting Boundaries
The combination of previsit patient coaching sessions and a question prompt list (QPL) leads to better patient-oncologist communication in advanced cancer, a study shows.

The cluster randomized controlled trial included 170 patients with advanced nonhaematologic cancer and their caregivers. The study participants were recruited from practices of 24 oncologists in New York. The intervention arm of the study included 12 oncologists who underwent individualized communication training and 84 patients who had individualized previsit coaching sessions with QPL. The other 12 oncologists and 86 patients in the control group received no interventions.

Results showed that 70.2 percent of patients in the intervention group brought up QPL-related topics compared with only 32.6 percent of patients in the control group (p<0.001). More patients in the intervention group (16.7 percent) asked about prognosis compared to the control group (5.8 percent; p=0.03).

A majority of the topics of interest identified during the previsit coaching were QPL-related and among these, 12.7 percent  involved prognosis.

Combining previsit individualized coaching and QPL intervention resulted in a more effective patient-oncologist dialogue. This helped advanced cancer patients and their caregivers identify and ask about topics of concern.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.